Spots Global Cancer Trial Database for tiragolumab matching placebo
Every month we try and update this database with for tiragolumab matching placebo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT04619797 | Non-small Cell ... | Tiragolumab Atezolizumab Pemetrexed Carboplatin Cisplatin Tiragolumab Mat... Pembrolizumab | 18 Years - | Hoffmann-La Roche | |
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | NCT04543617 | Esophageal Squa... | Tiragolumab Atezolizumab Tiragolumab Mat... Atezolizumab Ma... | 18 Years - | Hoffmann-La Roche | |
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | NCT04665856 | Small Cell Lung... | Tiragolumab Atezolizumab Carboplatin Etoposide Tiragolumab Mat... | 18 Years - | Hoffmann-La Roche | |
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | NCT04540211 | Esophageal Canc... | Atezolizumab Tiragolumab Paclitaxel Cisplatin Atezolizumab Ma... Tiragolumab Mat... | 18 Years - | Hoffmann-La Roche |